



**Charles Erlichman, MD, FRCPC, FACP**  
 Co-Chair for Experimental Therapeutics Committee  
 Mayo Clinic  
 200 First Street SW  
 Rochester, MN 55905  
 Phone: 507-266-3200  
 Email: Erlichman.charles@mayo.edu

**Gary Schwartz, MD**  
 Co-Chair for Experimental Therapeutics Committee  
 Columbia University  
 177 Ft. Washington Avenue, Suite 6-435  
 New York, NY 10032  
 Phone: 212-305-2055  
 Email: schwartzg@columbia.edu

**Date:** October 10, 2014

**To:** Experimental Therapeutics Committee

**From:** Charles Erlichman, M.D.  
 Gary Schwartz, M.D.

**Re:** **Experimental Therapeutics Committee Meeting**

**Date:** **Saturday, November 8, 2014**

**Time:** **8 am-11 am Central**

**Location:** Loews Chicago O'Hare - Rosemont, IL 60018  
 Room Louvre 1

**Call In Information: 800-501-8979 / 8087368**

**AGENDA**

1. Status update on activated current trials: *Horvath*

a.	A091104 (permanently closed to enrollment)	Phase II MK-2206 in Patients with progressive recurrent/metastatic Adenoid Cystic Carcinoma	A. Ho
b.	A091103 (permanently closed to accrual)	Phase 2 Study of Angiopoitein -1 and -2 peptibody AMG386 for the Treatment of Angiosarcoma	S. D'Angelo
c.	A091102 (suspended to accrual)	Phase II study of MLN8237 in advanced metastatic Sarcoma	M. Dickson
d.	A091101 (suspended to accrual)	TPF Induction chemotherapy and ABT-888- Phase 1/randomized Phase 2 Study in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck	J. de Souza

e.	N0871 (permanently closed to enrollment)	A Phase II Study of Carboplatin, Paclitaxel, and RAD001 in previously untreated Patients with Measurable Disease with Cancer of Unknown Primary (CUP)	M. Goetz
f.	N0879 (permanently closed to enrollment)	A Randomized Phase II Trial of Carboplatin, Paclitaxel, Bevacizumab, with or without Everolimus for Therapy of Metastatic Malignant Melanoma	R. McWilliams
g.	N1153	Phase I/II Study of Sorafenib + TH-302 in 1st line Advanced Hepatocellular Carcinoma (HCC) and 2nd line Renal Cell Carcinoma (RCC)	M. Borad
h.	A091201	Randomized Phase II study comparing the MET Inhibitor XL184 to DTIC in Uveal Melanoma	J. Luke
i.	A091105	Phase 3 double blind randomized placebo controlled trial of Sorafenib in Desmoid Tumors	M. Gounder
j.	A091305	A Phase 2 Double-Blind Randomized Study of Efatutazone, an Oral PPAR Agonist, in Combination with Paclitaxel versus Paclitaxel Plus Placebo in Patients with Advanced Anaplastic Thyroid Cancer	R. Smallridge
k.	A091302	Randomized Phase II study of Sorafenib with or without Everolimus in Patients with Radioactive Iodine Refractory Hürthle Cell Thyroid Cancer	E. Sherman

2. Status update on current trials in development: *Schwartz or Horvath*

a.	A091202	A Phase II Randomized Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, CS-7017 (Efatutazone) vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma	M. Pishvaian
b.	A091304	A Randomized Phase II Study of MLN-0128 vs. Pazopanib in Patients with Advanced Sarcoma	W. Tap
c.	A091401	A Phase II Study of Nivolumab With or Without Ipilimumab in Patients with Metastatic or Unresectable Sarcoma	S. D'Angelo

3. Status of Concepts: *Erlichman*

a.	Randomized Phase 2 study of chemo and androgen ablation in salivary gland cancer EORTC 1206/A091306	A. Ho
b.	Alternate Salivary Study with Enzalutamide	A. Ho
c.	B Smart	E. Horvath
d.	Reversing Resistance to Pazopanib with Histone Deacetylase Inhibition	P. Munster
e.	A Phase II study of cetuximab and lapatinib in patients with metastatic/recurrent Head and Neck Squamous Cell Carcinoma	J. Deeken

4. Update on NCI sponsored Match - *Schwartz*

5. Biomarker driven sarcoma trial proposal - *Horvath*